Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 83 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the LungTerminatedNCT02485652Phase 2
- Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseStatus unknownNCT02484755Phase 2
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
- Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
- Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsCompletedNCT02478866Phase 1
- A Pilot Trial of Curcumin Effects on Cognition in SchizophreniaTerminatedNCT02476708Not applicable
- Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast CancerCompletedNCT02476539Phase 1
- Study of Topical Ocular PAN-90806 in PDRCompletedNCT02475109Phase 1
- INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic FunctionCompletedNCT02474537Phase 1
- Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
- PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedNCT02472275Phase 1
- ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)Active, not recruitingNCT02471391Phase 2
- Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.SuspendedNCT02470065Phase 2
- Ruxolitinib in Combination With AutotransplantWithdrawnNCT02469974Not applicable
- A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
- A Study to Assess the Relative Bioavailability of JNJ-42756493 TabletsCompletedNCT02466815Phase 1
- Study of Regorafenib and Sildenafil for Advanced Solid TumorsCompletedNCT02466802Phase 1
- Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal CancerCompletedNCT02465502Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib TherapyStatus unknownNCT02461849Phase 2
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Phase 2/3
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid TumorsCompletedNCT02456883Phase 1
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
- Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) PatientsTerminatedNCT02454842Phase 2
- Phase 1 Study of CM082 in Patients With wAMDSuspendedNCT02452385Phase 1
- Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary CancerCompletedNCT02451553Phase 1
- Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaTerminatedNCT02451111Phase 2
- Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
- Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid TumorsCompletedNCT02450149Not applicable
- Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid TumorsCompletedNCT02450136Not applicable
- Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid TumorsCompletedNCT02450123Not applicable
- Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or SkinTerminatedNCT02449681Phase 2
- Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line TreatmentCompletedNCT02449551Phase 2
- Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)Status unknownNCT02449343Phase 2/3
- Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
- Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line ChemotherapyCompletedNCT02448329Phase 2
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung CancerTerminatedNCT02448251Phase 1
- Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid TumorsCompletedNCT02447419Phase 2
- Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
- Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
- CML Treated With Bosutinib After RelapseCompletedNCT02445742Phase 2
- Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer TherapyCompletedNCT02444819Phase 2
- A Phase 1 Study of KBP-5209 in Patients With Advanced Solid TumorsCompletedNCT02442414Phase 1
- Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer PatientsWithdrawnNCT02439723Phase 1
- Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable MetastasisCompletedNCT02439385Phase 2
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT02436707Phase 2
- ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With LeucovorinStatus unknownNCT02435927Phase 1
- A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET AmplificationCompletedNCT02435121Phase 2
- A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line ChemotherapyCompletedNCT02435108Phase 2
- Open Label Study of Fostamatinib in the Treatment of IgA NephropathyWithdrawnNCT02433236Phase 2
- Chemotherapy of NSCLC With or Without IcotinibStatus unknownNCT02430974Phase 2
- Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedNCT02428543Phase 1/2
- A Study of GSK2256098 and Trametinib in Advanced Pancreatic CancerCompletedNCT02428270Phase 2
- Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
- Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2
- Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular CarcinomaCompletedNCT02425605Phase 2
- First-in-Human Single Ascending Dose of SHR0302Status unknownNCT02423538Phase 1
- Safety Study of Afatinib for Brain CancerCompletedNCT02423525Phase 1
- Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknownNCT02422719Phase 2
- A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsCompletedNCT02422589Phase 1
- A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabStatus unknownNCT02422199Phase 1/2
- Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02421185Phase 1/2
- A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)CompletedNCT02421042Phase 1
- AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)WithdrawnNCT02420587Phase 2
- Pilot Study of Crizotinib in Relapsed ALK+ LymphomasCompletedNCT02419287Phase 2
- Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed RegimensCompletedNCT02418689Phase 2
- A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCompletedNCT02415023Phase 1/2
- Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTActive, not recruitingNCT02413736Phase 3
- A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric CancerStatus unknownNCT02409199Phase 2/3
- Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung CancerStatus unknownNCT02407366Phase 2
- Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCWithdrawnNCT02406508Phase 2
- Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric CarcinomaCompletedNCT02406170Phase 1/2
- High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Phase 4
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
- Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaStatus unknownNCT02399566Phase 4
- Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
- A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.Status unknownNCT02398552Phase 2
- Regorafenib Phase I Study in Mainland Chinese PatientsCompletedNCT02398513Phase 1
- Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast CancerStatus unknownNCT02396108Phase 1/2
- Overcoming Endocrine Resistance in Metastatic Breast CancerStatus unknownNCT02394496Phase 3
- Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland CarcinomaCompletedNCT02393820Phase 2
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
- Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）CompletedNCT02390947Phase 3
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy AdultsCompletedNCT02390609Phase 1
- Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to DasatinibStatus unknownNCT02389920Phase 4
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasCompletedNCT02389244Phase 2
- Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）CompletedNCT02388919Phase 2/3
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
- INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerCompletedNCT02386397Phase 1/2
- Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian CancerCompletedNCT02383251Phase 2
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
- Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyCompletedNCT02381080Phase 1
- Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
- Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
- Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Phase 1